Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Lexaria Bioscience Corp
(NQ:
LEXX
)
2.870
-0.190 (-6.21%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lexaria Bioscience Corp
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
29
30
Next >
Lexaria Receives Independent Review Board Approval for its Upcoming Human Oral Nicotine Study
November 01, 2022
Via
ACCESSWIRE
Lexaria Bioscience Corp. (NASDAQ: LEXX) Moves to Address Adverse Effects of Hypertension with DehydraTECH(TM) – CBD
October 31, 2022
Via
Investor Brand Network
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Successful Results of Human Clinical Hypertension Study
October 27, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria's Human Clinical Hypertension Study a Success
October 27, 2022
Via
ACCESSWIRE
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Potential Hypertension Medication Poised to Reduce Risk of Blood-Pressure-Induced Dementia, Cognitive Decline
October 25, 2022
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Holds Potential to Represent Multiple Commercial Opportunities
October 21, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Holds Potential to Represent Multiple Commercial Opportunities
October 21, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Using Novel DehydraTECH(TM) Technology to Address Unmet Antihypertension Drug Market
October 19, 2022
Via
Investor Brand Network
Flora Growth Corp. (NASDAQ: FLGC) Building Portfolio of Brands that Resonates with End Consumers as It Targets Margins and Profitability
October 19, 2022
Via
Investor Brand Network
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Drug Development Program Seeking to Provide Safe, Well-Tolerated, Effective Antihypertensive Medication Amid Continued Reports of Suboptimal Adherence to Existing Treatments
October 17, 2022
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Pipeline Addressing Severe Unmet Patient Needs
October 13, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Pipeline Addressing Severe Unmet Patient Needs
October 13, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Using Patented DehydraTECH(TM) Technology to Fight America’s Silent Killer – Hypertension
October 13, 2022
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Patented DehydraTECH(TM) Technology Offering Solutions to Growing Hypertension Problem Worldwide
October 11, 2022
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Working to Address Declining Antihypertensive Intensification and High Prescription Abandonment Rates, with DehydraTECH-CBD
October 07, 2022
Via
Investor Brand Network
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Redefining Drug Delivery Platforms
October 06, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Focusing on Multiple Mainstream Applications of Its Disruptive Patented DehydraTECH(TM) Technology
October 03, 2022
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Working to Expand Indications, Efficacy of DehydraTECH(TM)
September 30, 2022
Via
Investor Brand Network
Topics
Cannabis
Intellectual Property
Exposures
Cannabis
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Working to Expand Indications, Efficacy of DehydraTECH(TM)
September 30, 2022
Via
CannabisNewsWire
Topics
Cannabis
Intellectual Property
Exposures
Cannabis
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Addressing Hypertensive Patients’ Concerns with DehydraTECH-CBD
September 29, 2022
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Provide Bioavailable Oral Treatment for Hypertension, Mitigate Effects of High Blood Pressure
September 21, 2022
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting Hypertension Drug Market with Proprietary Drug-Delivery Method
September 20, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting Hypertension Drug Market with Proprietary Drug-Delivery Method
September 20, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience: Taking Aim at the $28 Billion Hypertension Market; Human Clinical Study Yields Remarkable Results
September 20, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
Product Safety
Lexaria Bioscience Corp. (NASDAQ: LEXX), Growing its Market Share, One Patent at a Time
September 16, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Hypertension Treatment Program Stands Distinct
September 15, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Hypertension Treatment Program Stands Distinct
September 15, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Lexaria Bioscience Corp. (NASDAQ: LEXX) Strengthens Board of Directors to Boost Efforts toward Regulatory Approval of Potential Treatment for Hypertension
September 14, 2022
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Acquires 27th Worldwide Patent Applying to a Range of APIs in Ready-to-Drink Consumer Retail Beverage Products
September 12, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Quest to Find Hypertension Treatment Promising With DehydraTECH(TM)’s Ability to Boost Bioavailability
September 06, 2022
Via
Investor Brand Network
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
29
30
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.